Formononetin induces apoptotic cell death through the suppression of mitogen‑activated protein kinase and nuclear factor‑κB phosphorylation in FaDu human head and neck squamous cell carcinoma cells

Oh,Ji‑Su; Kim,Tae‑Hyeon; Park,Jong‑Hyun; Lim,Hyangi; Cho,In‑A; You,Jae‑Seek; Lee,Gyeong‑Je; Seo,Yo‑Seob; Kim,Do   Kyung; Kim,Chun   Sung; Yu,Sun‑Kyoung; Kim,Heung‑Joong; Kim,Su‑Gwan; Kim,Jae‑Sung

doi:10.3892/or.2019.7432

Formononetin induces apoptotic cell death through the suppression of mitogen‑activated protein kinase and nuclear factor‑κB phosphorylation in FaDu human head and neck squamous cell carcinoma cells

Authors:
- Ji‑Su Oh
- Tae‑Hyeon Kim
- Jong‑Hyun Park
- Hyangi Lim
- In‑A Cho
- Jae‑Seek You
- Gyeong‑Je Lee
- Yo‑Seob Seo
- Do Kyung Kim
- Chun Sung Kim
- Sun‑Kyoung Yu
- Heung‑Joong Kim
- Su‑Gwan Kim
- Jae‑Sung Kim
View Affiliations

Affiliations: Department of Oral and Maxillofacial Surgery, School of Dentistry, Chosun University, Dong‑gu, Gwang‑Ju 61452, Republic of Korea, The Institute of Dental Science, School of Dentistry, Chosun University, Dong‑gu, Gwang‑Ju 61452, Republic of Korea, Department of Prosthodontics, School of Dentistry, Chosun University, Dong‑gu, Gwang‑Ju 61452, Republic of Korea, Department of Oral and Maxillofacial Radiology, School of Dentistry, Chosun University, Dong‑gu, Gwang‑Ju 61452, Republic of Korea
Published online on: December 13, 2019 https://doi.org/10.3892/or.2019.7432
Pages: 700-710

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Formononetin, a phytoestrogen extracted from various herbal plants, has been investigated as an anticancer agent against diverse types of cancer. The aim of the present study was to investigate the induction of apoptotic cell death by formononetin in the FaDu pharyngeal squamous cell carcinoma cell line. Formononetin significantly increased FaDu cell death, with an estimated IC50 value of 50 µM; however, it did not affect the viability of normal L929 mouse fibroblasts used as normal control at 5‑25 µM. Typical characteristics of apoptosis, such as morphological alterations, chromatin condensation, DNA fragmentation and the size of the apoptotic cell population, were increased in FaDu cells treated with formononetin for 24 h. Furthermore, formononetin‑induced FaDu cell death involved the death receptor‑mediated extrinsic and the mitochondria‑dependent intrinsic apoptotic pathways by activating the caspase cascade. The chemotherapeutic effects of formononetin were mediated by the suppression of mitogen‑activated protein kinases, including extracellular signal‑regulated kinase 1/2 and p38, and nuclear factor‑κB phosphorylation in FaDu cells. Finally, the oral administration of formononetin decelerated tumor growth through the expression of cleaved caspase‑3 in a FaDu cell xenograft animal model. Taken together, these findings indicate that formononetin holds promise as a chemotherapeutic agent and may be of value in the treatment of human head and neck squamous cell carcinoma.

View Figures

View References

1	Qi X, Jia B, Zhao X and Yu D: Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma. Onco Targets Ther. 10:5745–5754. 2017. View Article : Google Scholar : PubMed/NCBI
2	Bonomo P, Loi M, Desideri I, Olmetto E, Delli Paoli C, Terziani F, Greto D, Mangoni M, Scoccianti S, Simontacchi G, et al: Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review. Crit Rev Oncol Hematol. 120:98–110. 2017. View Article : Google Scholar : PubMed/NCBI
3	Belcher R, Hayes K, Fedewa S and Chen AY: Current treatment of head and neck squamous cell cancer. J Surg Oncol. 110:551–574. 2014. View Article : Google Scholar : PubMed/NCBI
4	Kundu SK and Nestor M: Targeted therapy in head and neck cancer. Tumour Biol. 33:707–721. 2012. View Article : Google Scholar : PubMed/NCBI
5	Shrotriya S, Agarwal R and Sclafani RA: A perspective on chemoprevention by resveratrol in head and neck squamous cell carcinoma. Adv Exp Med Biol. 815:333–348. 2015. View Article : Google Scholar : PubMed/NCBI
6	Li J, Jiang Z, Li X, Hou Y, Liu F, Li N, Liu X and Yang L: Natural therapeutic agents for neurodegenerative diseases from a traditional herbal medicine Pongamia pinnata (L.) Pierre. Bioorg Med Chem Lett. 25:53–58. 2015. View Article : Google Scholar : PubMed/NCBI
7	Li W, Sun YN, Yan XT, Yang SY, Kim S, Lee YM, Koh YS and Kim YH: Flavonoids from Astragalus membranaceus and their inhibitory effects on LPS-stimulated pro-inflammatory cytokine production in bone marrow-derived dendritic cells. Arch Pharm Res. 37:186–192. 2014. View Article : Google Scholar : PubMed/NCBI
8	Ghribi L, Waffo-Teguo P, Cluzet S, Marchal A, Marques J, Mérillon JM and Ben Jannet H: Isolation and structure elucidation of bioactive compounds from the roots of the Tunisian Ononis angustissima L. Bioorg Med Chem Lett. 25:3825–3830. 2015. View Article : Google Scholar : PubMed/NCBI
9	Tava A, Pecio L, Stochmal A and Pecetti L: Clovamide and flavonoids from leaves of Trifolium pratense and T. pratense subsp. Nivale grown in Italy. Nat Prod Commun. 10:933–936. 2015.PubMed/NCBI
10	Mu H, Bai YH, Wang ST, Zhu ZM and Zhang YW: Research on antioxidant effects and estrogenic effect of formononetin from Trifolium pratense (red clover). Phytomedicine. 16:314–319. 2009. View Article : Google Scholar : PubMed/NCBI
11	Xu N and An J: Formononetin ameliorates mast cell-mediated allergic inflammation via inhibition of histamine release and production of pro-inflammatory cytokines. Exp Ther Med. 14:6201–6206. 2017.PubMed/NCBI
12	Ma Z, Ji W, Fu Q and Ma S: Formononetin inhibited the inflammation of LPS-induced acute lung injury in mice associated with induction of PPAR gamma expression. Inflammation. 36:1560–1566. 2013. View Article : Google Scholar : PubMed/NCBI
13	Sun M, Zhou T, Zhou L, Chen Q, Yu Y, Yang H, Zhong K, Zhang X, Xu F, Cai S, et al: Formononetin protects neurons against hypoxia-induced cytotoxicity through upregulation of ADAM10 and sAβPPα. J Alzheimers Dis. 28:795–808. 2012. View Article : Google Scholar : PubMed/NCBI
14	Wu J, Ke X, Ma N, Wang W, Fu W, Zhang H, Zhao M, Gao X, Hao X and Zhang Z: Formononetin, an active compound of Astragalus membranaceus (Fisch) Bunge, inhibits hypoxia-induced retinal neovascularization via the HIF-1α/VEGF signaling pathway. Drug Des Devel Ther. 10:3071–3081. 2016. View Article : Google Scholar : PubMed/NCBI
15	Wu Y, Zhang X, Li Z, Yan H, Qin J and Li T: Formononetin inhibits human bladder cancer cell proliferation and invasiveness via regulation of MiR-21 and PTEN. Food Funct. 8:1061–1066. 2017. View Article : Google Scholar : PubMed/NCBI
16	Yang Y, Zhao Y, Ai X, Cheng B and Lu S: Formononetin suppresses the proliferation of human non-small cell lung cancer through induction of cell cycle arrest and apoptosis. Int J Clin Exp Pathol. 7:8453–8461. 2014.PubMed/NCBI
17	Li T, Zhao X, Mo Z, Huang W, Yan H, Ling Z and Ye Y: Formononetin promotes cell cycle arrest via downregulation of Akt/Cyclin D1/CDK4 in human prostate cancer cells. Cell Physiol Biochem. 34:1351–1358. 2014. View Article : Google Scholar : PubMed/NCBI
18	Zhou R, Xu L, Ye M, Liao M, Du H and Chen H: Formononetin inhibits migration and invasion of MDA-MB-231 and 4T1 breast cancer cells by suppressing MMP-2 and MMP-9 through PI3K/AKT signaling pathways. Horm Metab Res. 46:753–760. 2014. View Article : Google Scholar : PubMed/NCBI
19	Jin YM, Xu TM, Zhao YH, Wang YC and Cui MH: In vitro and in vivo anti-cancer activity of formononetin on human cervical cancer cell line HeLa. Tumour Biol. 35:2279–2284. 2014. View Article : Google Scholar : PubMed/NCBI
20	Auyeung KK, Law PC and Ko JK: Novel anti-angiogenic effects of formononetin in human colon cancer cells and tumor xenograft. Oncol Rep. 28:2188–2194. 2012. View Article : Google Scholar : PubMed/NCBI
21	Lydiatt WM, Patel SG, O'Sullivan B, Brandwein MS, Ridge JA, Migliacci JC, Loomis AM and Shah JP: Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin. 67:122–137. 2017. View Article : Google Scholar : PubMed/NCBI
22	Martino R and Ringash J: Evaluation of quality of life and organ function in head and neck squamous cell carcinoma. Hematol Oncol Clin North Am. 22:1239–1256. 2008. View Article : Google Scholar : PubMed/NCBI
23	Soni M, Rahardjo TB, Soekardi R, Sulistyowati Y, Lestariningsih, Yesufu-Udechuku A, Irsan A and Hogervorst E: Phytoestrogens and cognitive function: A review. Maturitas. 77:209–220. 2014. View Article : Google Scholar : PubMed/NCBI
24	Sirotkin AV and Harrath AH: Phytoestrogens and their effects. Eur J Pharmacol. 741:230–236. 2014. View Article : Google Scholar : PubMed/NCBI
25	Qadir MI and Cheema BN: Phytoestrogens and related food components in the prevention of cancer. Crit Rev Eukaryot Gene Expr. 27:99–112. 2017. View Article : Google Scholar : PubMed/NCBI
26	Cho IA, You SJ, Kang KR, Kim SG, Oh JS, You JS, Lee GJ, Seo YS, Kim DK, Kim CS, et al: Biochanin-A induces apoptosis and suppresses migration in FaDu human pharynx squamous carcinoma cells. Oncol Rep. 38:2985–2992. 2017. View Article : Google Scholar : PubMed/NCBI
27	Huh JE, Nam DW, Baek YH, Kang JW, Park DS, Choi DY and Lee JD: Formononetin accelerates wound repair by the regulation of early growth response factor-1 transcription factor through the phosphorylation of the ERK and p38 MAPK pathways. Int Immunopharmacol. 11:46–54. 2011. View Article : Google Scholar : PubMed/NCBI
28	Huh JE, Seo DM, Baek YH, Choi DY, Park DS and Lee JD: Biphasic positive effect of formononetin on metabolic activity of human normal and osteoarthritic subchondral osteoblasts. Int Immunopharmacol. 10:500–507. 2010. View Article : Google Scholar : PubMed/NCBI
29	Hu W and Xiao Z: Formononetin induces apoptosis of human osteosarcoma cell line U2OS by regulating the expression of Bcl-2, Bax and MiR-375 in vitro and in vivo. Cell Physiol Biochem. 37:933–939. 2015. View Article : Google Scholar : PubMed/NCBI
30	Liu XJ, Li YQ, Chen QY, Xiao SJ and Zeng SE: Up-regulating of RASD1 and apoptosis of DU-145 human prostate cancer cells induced by formononetin in vitro. Asian Pac J Cancer Prev. 15:2835–2839. 2014. View Article : Google Scholar : PubMed/NCBI
31	Chen J, Zhao X, Ye Y, Wang Y and Tian J: Estrogen receptor beta-mediated proliferative inhibition and apoptosis in human breast cancer by calycosin and formononetin. Cell Physiol Biochem. 32:1790–1797. 2013. View Article : Google Scholar : PubMed/NCBI
32	Bortner CD and Cidlowski JA: Cell shrinkage and monovalent cation fluxes: Role in apoptosis. Arch Biochem Biophys. 462:176–188. 2007. View Article : Google Scholar : PubMed/NCBI
33	Kass GE, Eriksson JE, Weis M, Orrenius S and Chow SC: Chromatin condensation during apoptosis requires ATP. Biochem J. 318:749–752. 1996. View Article : Google Scholar : PubMed/NCBI
34	Higuchi Y: Chromosomal DNA fragmentation in apoptosis and necrosis induced by oxidative stress. Biochem Pharmacol. 66:1527–1535. 2003. View Article : Google Scholar : PubMed/NCBI
35	Chai F, Truong-Tran AQ, Ho LH and Zalewski PD: Regulation of caspase activation and apoptosis by cellular zinc fluxes and zinc deprivation: A review. Immunol Cell Biol. 77:272–278. 1999. View Article : Google Scholar : PubMed/NCBI
36	Pfeffer CM and Singh ATK: Apoptosis: A target for anticancer therapy. Int J Mol Sci. 19:4482018. View Article : Google Scholar :
37	Zaman S, Wang R and Gandhi V: Targeting the apoptosis pathway in hematologic malignancies. Leuk Lymphoma. 55:1980–1992. 2014. View Article : Google Scholar : PubMed/NCBI
38	Goldar S, Khaniani MS, Derakhshan SM and Baradaran B: Molecular mechanisms of apoptosis and roles in cancer development and treatment. Asian Pac J Cancer Prev. 16:2129–2144. 2015. View Article : Google Scholar : PubMed/NCBI
39	Liu H, Su D, Zhang J, Ge S, Li Y, Wang F, Gravel M, Roulston A, Song Q, Xu W, et al: Improvement of pharmacokinetic profile of TRAIL via trimer-tag enhances its antitumor activity in vivo. Sci Rep. 7:89532017. View Article : Google Scholar : PubMed/NCBI
40	Hassan M, Watari H, AbuAlmaaty A, Ohba Y and Sakuragi N: Apoptosis and molecular targeting therapy in cancer. Biomed Res Int. 2014:1508452014. View Article : Google Scholar : PubMed/NCBI
41	Green DR and Llambi F: Cell death signaling. Cold Spring Harb Perspect Biol. 1:a0060802015. View Article : Google Scholar
42	Suhaili SH, Karimian H, Stellato M, Lee TH and Aguilar MI: Mitochondrial outer membrane permeabilization: A focus on the role of mitochondrial membrane structural organization. Biophys Rev. 9:443–457. 2017. View Article : Google Scholar : PubMed/NCBI
43	Czabotar PE, Colman PM and Huang DC: Bax activation by Bim? Cell Death Differ. 16:1187–1191. 2009. View Article : Google Scholar : PubMed/NCBI
44	Gogada R, Yadav N, Liu J, Tang S, Zhang D, Schneider A, Seshadri A, Sun L, Aldaz CM, Tang DG and Chandra D: Bim, a proapoptotic protein, up-regulated via transcription factor E2F1-dependent mechanism, functions as a prosurvival molecule in cancer. J Biol Chem. 288:368–381. 2013. View Article : Google Scholar : PubMed/NCBI
45	Zhang X, Bi L, Ye Y and Chen J: Formononetin induces apoptosis in PC-3 prostate cancer cells through enhancing the Bax/Bcl-2 ratios and regulating the p38/Akt pathway. Nutr Cancer. 66:656–661. 2014. View Article : Google Scholar : PubMed/NCBI
46	Peng Q, Deng Z, Pan H, Gu L, Liu O and Tang Z: Mitogen-activated protein kinase signaling pathway in oral cancer. Oncol Lett. 15:1379–1388. 2018.PubMed/NCBI
47	Huang RH, Quan YJ, Chen JH, Wang TF, Xu M, Ye M, Yuan H, Zhang CJ, Liu XJ and Min ZJ: Osteopontin promotes cell migration and invasion, and inhibits apoptosis and autophagy in colorectal cancer by activating the p38 MAPK signaling pathway. Cell Physiol Biochem. 41:1851–1864. 2017. View Article : Google Scholar : PubMed/NCBI
48	Lv D, Wu H, Xing R, Shu F, Lei B, Lei C, Zhou X, Wan B, Yang Y, Zhong L, et al: HnRNP-L mediates bladder cancer progression by inhibiting apoptotic signaling and enhancing MAPK signaling pathways. Oncotarget. 8:13586–13599. 2017.PubMed/NCBI
49	Chen H, Jin ZL and Xu H: MEK/ERK signaling pathway in apoptosis of SW620 cell line and inhibition effect of resveratrol. Asian Pac J Trop Med. 9:49–53. 2016. View Article : Google Scholar : PubMed/NCBI
50	Sun XF and Zhang H: NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol. 22:1387–1398. 2007.PubMed/NCBI
51	Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS and Workman P: Targeting the PI3K-AKT-mTOR pathway: Progress, pitfalls, and promises. Curr Opin Pharmacol. 8:393–412. 2008. View Article : Google Scholar : PubMed/NCBI
52	Alam M, Kashyap T, Pramanik KK, Singh AK, Nagini S and Mishra R: The elevated activation of NFkB and AP-1 is correlated with differential regulation of Bcl-2 and associated with oral squamous cell carcinoma progression and resistance. Clin Oral Investig. 21:2721–2731. 2017. View Article : Google Scholar : PubMed/NCBI
53	Wu XY, Xu H, Wu ZF, Chen C, Liu JY, Wu GN, Yao XQ, Liu FK, Li G and Shen L: Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models. Oncotarget. 6:44563–44578. 2015. View Article : Google Scholar : PubMed/NCBI
54	Tyagi A, Gu M, Takahata T, Frederick B, Agarwal C, Siriwardana S, Agarwal R and Sclafani RA: Resveratrol selectively induces DNA damage, independent of Smad4 expression, in its efficacy against human head and neck squamous cell carcinoma. Clin Cancer Res. 17:5402–5411. 2011. View Article : Google Scholar : PubMed/NCBI